While selumetinib showed a strong impact on pERK as a pharmacodynamic marker in the AML cells (Fig. 7E), mice treated with ruxolitinib, and the combination did not show statistically significant changes by phospho-flow staining for p-STAT5 (Fig. 7F) suggesting that JAK2 signaling was not sufficiently suppressed. The gene discussed is JAK2; the disease is acute myeloid leukemia.